Our Pricing

Switching from 10mg Mounjaro to Wegovy: UK Clinical Guidance and Weight Loss Results

Transitioning from 10mg Mounjaro to Wegovy is a common consideration for patients seeking to optimise their weight loss treatment in the UK. Both medications are GLP-1 receptor agonists, but they differ in active ingredient (tirzepatide vs semaglutide), dosing schedules, and cost — understanding the clinical equivalence and expected outcomes is essential for making an informed switch under prescriber guidance.

Understanding the 10mg Mounjaro to Wegovy Transition

When switching from 10mg Mounjaro to Wegovy, patients are moving from tirzepatide (a dual GIP/GLP-1 receptor agonist) to semaglutide (a pure GLP-1 receptor agonist). The 10mg dose of Mounjaro represents a mid-range maintenance dose, typically achieved after 16-20 weeks of dose escalation[1]. Wegovy's dosing schedule differs, with a maximum maintenance dose of 2.4mg once weekly, reached through a separate titration protocol starting at 0.25mg[2].

There is no direct milligram-for-milligram equivalence between 10mg Mounjaro to Wegovy because the medications work through different receptor mechanisms and have distinct pharmacokinetic profiles. Clinical guidance from UK prescribers typically recommends starting Wegovy at the initial 0.25mg dose rather than attempting to match the Mounjaro dose numerically, allowing the body to adjust to the new medication and minimise gastrointestinal side effects[3]. This transition must always be supervised by a UK-registered prescriber who can assess individual patient factors including weight loss progress, tolerability, and treatment goals.

Clinical Evidence: 10mg Mounjaro to Wegovy Weight Loss Outcomes

Patients considering the switch from 10mg Mounjaro to Wegovy often ask about comparative weight loss results. In the SURPASS-2 trial, tirzepatide 10mg demonstrated average weight reductions of 9.5kg (approximately 10% body weight) over 40 weeks in adults with type 2 diabetes[1]. The STEP 1 trial showed that semaglutide 2.4mg (Wegovy's maintenance dose) achieved average weight loss of 14.9% of initial body weight over 68 weeks in adults without diabetes[2].

When transitioning from 10mg Mounjaro to Wegovy, UK clinical experience suggests that patients who have already achieved significant weight loss on Mounjaro may experience continued, though potentially slower, weight reduction on Wegovy. The transition period itself — typically 4-8 weeks while titrating Wegovy from 0.25mg to the maintenance dose — may see a temporary plateau in weight loss before resuming a downward trend[4]. Individual results vary based on adherence to lifestyle modifications, baseline metabolic factors, and duration on each medication.

Expected Timeline for Wegovy After 10mg Mounjaro

After discontinuing 10mg Mounjaro, UK prescribers typically recommend waiting 5-7 days before starting Wegovy at 0.25mg, allowing tirzepatide to clear from the system and reducing the risk of overlapping side effects. The Wegovy dose escalation schedule then progresses monthly: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, and finally 2.4mg maintenance[2]. Patients transitioning from 10mg Mounjaro to Wegovy should expect the full dose titration to take approximately 16-20 weeks, during which weight loss may continue at a rate of 0.5-1kg per week, subject to individual response and prescriber assessment.

Comparing 10mg Mounjaro to Wegovy: Efficacy and Tolerability

The decision to switch from 10mg Mounjaro to Wegovy in the UK often hinges on efficacy, side effect profile, and cost considerations. Tirzepatide's dual receptor mechanism (GIP and GLP-1) has shown superior weight loss in head-to-head trials compared to semaglutide, with the SURPASS-2 study demonstrating greater reductions in HbA1c and body weight with tirzepatide 10mg and 15mg versus semaglutide 1mg[1]. However, Wegovy at 2.4mg — a higher dose than the 1mg used in that comparison — has demonstrated robust weight loss outcomes in its own right.

Tolerability profiles are similar between the two medications when transitioning from 10mg Mounjaro to Wegovy, with nausea, diarrhoea, and constipation being the most common gastrointestinal side effects reported in clinical trials[2][3]. Some UK patients report that the switch to Wegovy offers improved tolerability if they experienced persistent nausea on Mounjaro, though this is highly individual. The slower dose escalation with Wegovy may provide better gastrointestinal adaptation for patients who found the Mounjaro titration schedule challenging.

Practical Guidance for the 10mg Mounjaro to Wegovy Switch in the UK

UK patients switching from 10mg Mounjaro to Wegovy should work closely with their prescriber to create a personalised transition plan. Key practical considerations include timing the switch to avoid disruption to weight loss momentum, managing any withdrawal or adaptation symptoms during the changeover period, and maintaining consistent lifestyle interventions (calorie reduction and physical activity) throughout the transition[4].

At Cured Pharmacy, our UK-registered clinical team provides free online consultations to assess suitability for transitioning from 10mg Mounjaro to Wegovy. The consultation takes under 3 minutes and ensures that the switch is clinically appropriate based on your weight loss history, current health status, and treatment goals. All prescriptions are issued by UK-registered prescribers following MHRA and NICE guidelines, with genuine UK-licensed medications dispensed from our GPhC-registered pharmacy (9012511).

Monitoring Weight Loss During the 10mg Mounjaro to Wegovy Transition

Effective monitoring during the switch from 10mg Mounjaro to Wegovy includes weekly weight measurements, tracking of side effects, and regular prescriber check-ins at each dose escalation. UK clinical guidance recommends continuing the medication only if at least 5% body weight loss is achieved within 12 weeks of reaching the maintenance dose, and 10% loss by 6 months[3]. Patients should also monitor for signs of dehydration, gallbladder issues, or changes in blood glucose (particularly if diabetic), reporting any concerns to their healthcare provider immediately.

Cost Comparison: 10mg Mounjaro to Wegovy UK Pricing

Cost is a significant factor when considering the transition from 10mg Mounjaro to Wegovy in the UK. At Cured Pharmacy, Mounjaro is available from £225.00 per month, whilst Wegovy starts from £225.00 per month, representing substantial savings for patients making the switch. Both medications require ongoing monthly prescriptions, and the total cost of treatment should be considered alongside clinical efficacy and individual response.

Cured Pharmacy offers the cheapest UK price on both Mounjaro and Wegovy, with transparent upfront pricing displayed before consultation. New patients can Save £20 off their first order with code Weightlossnew, and our lowest price guarantee ensures you won't find these medications cheaper elsewhere in the UK. All prices include the clinical consultation, prescription, and discreet next-day delivery across the UK.

Who Should Consider Switching from 10mg Mounjaro to Wegovy?

The decision to switch from 10mg Mounjaro to Wegovy should be based on clinical factors rather than cost alone. Suitable candidates include patients who have achieved their target weight on Mounjaro and wish to transition to a more cost-effective maintenance option, those experiencing persistent side effects on tirzepatide who may tolerate semaglutide better, or patients for whom Mounjaro is temporarily unavailable due to UK supply constraints[4].

Conversely, patients who are still actively losing weight on 10mg Mounjaro and tolerating it well may be advised to continue their current treatment, particularly if planning to escalate to the 12.5mg or 15mg doses for additional weight loss. UK prescribers will assess each case individually, considering weight loss trajectory, metabolic parameters, side effect burden, and patient preference. At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team ensure every transition from 10mg Mounjaro to Wegovy is evidence-based and aligned with MHRA guidance.

Long-Term Maintenance: Wegovy After 10mg Mounjaro Success

For patients who have successfully reached their weight loss goals on 10mg Mounjaro, transitioning to Wegovy can serve as a long-term maintenance strategy. Clinical data suggests that continued GLP-1 receptor agonist therapy is necessary to maintain weight loss, with significant weight regain observed upon discontinuation[2]. Wegovy's lower cost compared to higher-dose Mounjaro makes it an attractive option for sustained weight management in the UK, subject to ongoing prescriber review and adherence to lifestyle modifications that support long-term metabolic health.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.